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Neurotransmitter receptors are essential for mediating the effects of neurotransmitters in the brain and peripheral nervous system. There are generally considered to be two 
types of neurotransmitter receptors: ionotropic and metabotropic. 
While ionotropic receptors are typically ligand-gated ion chan-
nels, through which ions pass in response to a neurotransmitter, 
metabotropic receptors need G proteins and second messengers to 
indirectly modulate ionic activity in neurons. G protein–coupled 
receptors (GPCRs) represent the largest family of metabotropic 
receptors, although receptor tyrosine kinases1 and guanylate cyclase 
receptors2,3 can also be considered metabotropic receptors4. GPCRs 
also constitute the largest family of druggable targets5,6 encoded by 
the human genome, and 34% of medications approved by the US 
Food and Drug Administration have GPCRs as their main thera-
peutic target7,8, especially those used for the treatment of neuropsy-
chiatric disorders6,9,10 (Table 1).
There are many distinct chemical classes of neurotransmitters, 
including the following: (1) small molecules (e.g., glutamate, nor-
epinephrine and serotonin); (2) neuropeptides (e.g., enkephalins, 
endorphins and neurokinins); and (3) others, including metabolites 
(e.g., endocannabinoids, ATP, ADP and adenosine) and gases (e.g., 
nitric oxide). Although the precise number of brain neurotransmit-
ters is not known with certainty, it is likely that hundreds of distinct 
neurotransmitters exist, including many ‘orphan’ neuropeptides11. 
Each neurotransmitter system has distinct cellular and region-spe-
cific distribution patterns in the brain; these can be visualized at the 
mRNA level with the Allen Brain Atlas12 or via genetically encoded 
markers with the GENSAT (Gene Expression Nervous System 
Atlas) resource13. Almost all neurotransmitters transduce their sig-
nals at least in part by activating GPCRs, and the regional and cellu-
lar distributions of brain GPCR mRNAs are well described12,14. As is 
the case with neurotransmitters, each of the metabotropic receptors 
for neurotransmitters has a distinct regional and cellular distribu-
tion in the brain12,14 and elsewhere14.
GPCRs modulate synaptic transmission via so-called ‘slow 
synaptic transmission’15, which occurs in a time frame of seconds 
to minutes in the central nervous system. Metabotropic receptors 
such as GPCRs may be found pre- and post-synaptically. Pre-synaptic 
Gi-coupled GPCRs, such as the 5-HT1A and 5-HT1B serotonin 
receptors16,17, inhibit neurotransmitter release via Gβ/γ-mediated 
activation of inhibitory channels, such as G protein–coupled 
inwardly rectifying potassium channels18, and via the inhibition of 
vesicle-docking SNARE-like proteins19,20 (Fig. 1). Post-synaptically, 
GPCRs can enhance neuronal excitability via Gs- and Gq-coupled 
GPCRs, which have complex actions mediated by second messen-
gers and protein kinases21,22 (Fig. 1).
This Review will discuss how structural insights into neurotrans-
mitter GPCRs have transformed the understanding of these recep-
tors, focusing on example GPCRs that are targets of drugs approved 
for use in the treatment of neuropsychiatric disorders. The past 
decade has witnessed remarkable progress in elucidating the struc-
ture and function of GPCR family, with perhaps 60 or so GPCRs 
having their structures determined by X-ray crystallography7 or 
cryo-EM7. Additionally, various intermediate signaling states, 
ranging from inactive to active, have been elucidated for exem-
plar GPCRs6. Finally, progress has been made on the use of such 
structural information for structure-guided and structure-inspired 
neuropsychiatric drug discovery8. This Review will provide an over-
view of the understanding of how structure informs the function 
of representative neurotransmitter GPCRs. It will also show how 
an understanding of structure elucidates neuropharmacology and 
will highlight therapeutic challenges and opportunities for neuro-
transmitter-targeted GPCRs.
Structural genomics of neurotransmitter-targeted GPCRs
Structural genomics has been defined as the approach that proposes 
‘determining protein structures on a genome-wide scale’23, which 
boils down to ultimately determining the three-dimensional struc-
ture of every protein encoded by the human genome. Obtaining 
GPCR structures has been historically challenging. Thus, although 
low-resolution structures of rhodopsin were available as early as 
1993 (ref. 24), and useful models of helical arrangements were gen-
erated through the use of that information25, the first bona fide 
high-resolution GPCR structure was not achieved until 2000, with 
rhodopsin26. The first non-opsin GPCR structures were obtained 
in 2007 (refs. 27–29), and since then, structures have been obtained, 
mainly via X-ray crystallography, for around 60 distinct human 
GPCRs7 (Fig. 2a). To generate useful structures, GPCR crystallog-
raphy typically requires high-affinity ligands, which serve to stabi-
lize the receptor in a distinct state suitable for crystallography. Such 
compounds not only need to be of high affinity (e.g., in the low 
nanomolar to picomolar range) but also need to have slow dissocia-
tion rates30. Ideally, then, to obtain complete structural coverage of 
all GPCRs encoded by the human genome, one would need high-
affinity, slowly dissociating ligands for each of them. Such ligands 
do not necessarily need to be specific, as, for example, the non-
selective drug ergotamine has been used to obtain the structures of 
three different serotonin receptor subtypes: 5-HT1B (ref. 31, 5-HT2B 
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(ref. 32) and 5-HT2C (ref. 33). Once structures are obtained, even with 
non-selective ligands, the structural features for distinct pharmaco-
logical properties can be elucidated (as in refs. 32,33). Furthermore, 
obtaining structures of related GPCRs frequently facilitates the 
structure-guided discovery and design of subtype-selective drugs34.
An analysis of available GPCR structures and cognate ligands, 
done with open-source databases of small molecules that bind 
known protein targets, along with databases of GPCR structural 
information, can be the first step toward determining the feasibil-
ity of a comprehensive structural elucidation of the ‘GPCR-ome’. 
Chembl35, the KiDatabase36 and PubChem37 are databases that 
match compounds and their targets. Figure 2a shows the number 
of ligands with Chembl-annotated activity, plotted against a total 
of 393 non-olfactory GPCRs and, simultaneously, the number 
of structures available for each of these receptors (as of February 
2019). Similar to previously published analyses6–8,38,39, in this analy-
sis, around half of all human non-olfactory GPCRs are well anno-
tated with respect to chemical matter, while the rest have few to no 
compounds associated with them in openly available databases35. 
With one exception—the receptor FZD4 (Frizzled 4), for which 
the structure of the seven-transmembrane domain (TM7) in the 
ligand-free state has been solved40—those GPCRs for which there 
are reported structures typically have hundreds to thousands of 
annotated ligands (Fig. 2a). No clear relationship exists between 
the number of annotated ligands in Chembl and the number 
of distinct structures (Fig. 2b), although, as mentioned above, 
high-affinity, slowly dissociating ligands are typically key for 
obtaining structures. Thus, comprehensive elucidation of the 
structural genomics of GPCRs will require that suitable ligands 
be obtained for a large number of these receptors. Efforts are now 
ongoing to obtain these ligands, including the ‘Illuminating the 
Druggable Genome’ initiative (https://commonfund.nih.gov/idg), 
which has designated those GPCRs for which there is little chemical 
matter a top priority.
Taking into account the wealth of data noted above, and with 
new GPCR structures now appearing every week or so, what are 
the opportunities and challenges for the completion of a structural 
genomics survey for neurotransmitter GPCRs? Even for the 240 
class A (Rhodopsin-like) GPCRs, which comprise most neurotrans-
mitter receptors and for which there is the most structural cover-
age, fewer than 50 distinct members have elucidated structures. 
Several classes — B2 (Adhesion), C (Glutamate), F (Frizzled) and T 
Table 1 | Representative metabotropic neurotransmitter receptors as targets for neuropsychiatric disorders and drugs of abuse
target class Neurotransmitter Receptor Representative 
medication






GPCR Dopamine D2 dopamine Ropinirole Parkinson’s Disease Agonist 75
GPCR Dopamine D2 dopamine Nemonapride Schizophrenia Antagonist/
inverse agonist
75
GPCR Serotonin 5-HT2C serotonin Lorcaserin Obesity Agonist 33
GPCR Serotonin 5-HT1A serotonin Buspirone Anxiety and depression Partial agonist None reported
GPCR Serotonin 5-HT1B Ergotamine Migraine headaches Antagonist 31,32
GPCR Adenosine A2A adenosine Caffeine Alertness Antagonist 131
GPCR Norepinephrine β1 and β2  
adrenergic
Propranolol Post-traumatic stress 
disorder; anxiety disorders
Inverse agonist 132,133
GPCR Serotonin 5-HT2A serotonin Pimavanserin Psychosis related to 
Parkinson’s Disease
Inverse agonist 134
GPCR Serotonin Many 5-HT 
receptors
LSD Hallucinogen use and 
abuse
Agonist 70




GPCR GABA GABA-B Baclofen Spasticity-related 
movement disorders
Agonist None reported
GPCR Histamine H1-histamine Diphenhydramine Sedative Antagonist 41
GPCR Endorphins; 
endomorphans
μ-opioid Morphine Pain; abused opioid Agonist 59,136
GPCR Dynorphin κ-opioid Nalfurafine Itch Agonist 52,137
GPCR Dynorphin κ-opioid Salvinorin A Hallucinogen use and 
abuse
Agonist 52,137
GPCR Orexin OX1 orexin Suvorexant Insomnia Antagonist 138
GPCR Norepinephrine α2 adrenergic Clonidine Anxiety; opioid withdrawal Agonist None reported
GPCR S1P1 sphingosine 
antagonist








TRK Entrectinib Cancers including 
astrocytoma











None (heart failure) Agonist 140
GABA, γ-amino butyric acid.
(Tastant 2), for example — have two reported structures (Glutamate 
and Frizzled) to no reported structures (Adhesion and Tastant).
Even among the thoroughly structurally annotated families of 
neurotransmitter receptors, such as the biogenic amine receptor 
family, structural annotation is still very sparse. Thus, only one (the 
H1 histamine receptor)41 of four histamine receptors has a reported 
structure, and there are no publicly available structures for α1 or 
α2 adrenergic receptors. Finally, among 14 serotonin receptors17, 
only 3 (5-HT1B, 5-HT2B and 5-HT2C)31–33 have published structures. 
Thus, considerable opportunities exist for obtaining structures of 
representative members of each neurotransmitter GPCR subfam-
ily. Additionally, even for neurotransmitter receptor families such as 
the muscarinic receptor family, which has acetylcholine as its neu-
rotransmitter and for which four (M1, M2, M3 and M4)42–44 of five 
members have structures reported, the structural determinants for 
subtype selectivity are still to be elucidated and fully exploited for 
the creation of selective muscarinic agonists and antagonists45. For 
muscarinic receptors, in particular, it is clear that drugs targeting 
M1 and M4 muscarinic receptors may have special utility for the 
enhancement of cognition in Alzheimer’s disease and schizophre-
nia, while interactions with M3 muscarinic receptors are associated 
with debilitating side effects46,47. In terms of creating subtype-selec-
tive drugs, a variety of structure-guided approaches can be used, 
including targeting allosteric and orthosteric sites (as discussed 
in refs. 6,8,48). As the foregoing makes clear, although considerable 
progress has been made toward a comprehensive understanding 
of the structural genomics of human neurotransmitter GPCRs, a 
vast amount of work remains, which will require the integrated and 
coordinated efforts of structural biologists, pharmacologists, chem-
ists and computational biologists.
Structural insights into activation and biased signaling
As with GPCR structural genomics, considerable insight into the 
structural features of neurotransmitter-targeted GPCR activation 
and biased signaling has been obtained. As for GPCR activation, 
the first structure of a GPCR in complex with hetereotrimeric 
G proteins was obtained in 2011 (ref. 49), and since then, several 
structures of nanobody-stabilized active states (e.g., β2 adrenergic 
receptors50, M2 muscarinic receptors51 and κ- and μ-opioid recep-
tors52,53) and heterotrimeric G protein–stabilized active states (e.g., 
calcitonin receptors54, CGRP (calcitonin gene–related peptide) 
receptors55,56, the 5-HT1B serotonin receptor57,58, μ-opioid receptors59 
and the GLP-1 (glucagon-like peptide-1) receptor60) have appeared, 
essentially all with neurotransmitter-targeted GPCRs. Furthermore, 
structures of arrestin-biased agonists at the receptor 5-HT2B 
(refs. 32,61,62), arrestin-bound rhodopsin63 and G protein–biased 
agonists at the GLP-1 receptor64 have been reported. Finally, there 
are inactive-state structures stabilized by sodium (e.g., A2A adenos-
ine receptors65, δ-opioid receptors66 and D4 dopamine receptors34), 
negatively modulating allosteric nanobodies at the β2 adrener-
gic receptor67 and the ligand-free basal structure of the receptor 
FZD440. Figure 3 depicts representative structures of these various 
states, along with a graphical representation of an extended ter-
nary complex model of receptor activation that includes complexes 
stabilized by both G protein68 and β-arrestin69. The outward 
movement of TM6 is the hallmark for GPCR activation, as are 
several other canonical rearrangements49,53. These include rear-
rangements of several microswitches32 such as the ‘P-I-F’ motif, 
formed by residues P5.50, I3.40 and F6.44 (Fig. 4). Here there is an 
inward shift of P5.50, along with a rotamer switch of I3.40 and a large 
inward movement of F6.44. Additional microswitches that undergo 
rearrangement include the D(E)/RY motif in TM3 and the NPxxY 
motif in TM7. The salt bridge between D3.49 and R3.50 is typically 
broken in active-state structures49,53. At the NPxxY motif, activation 
reveals a rotation of Y7.53. Additionally the sodium site collapses due 






















Fig. 1 | Metabotropic receptors such as GPCRs modulate synaptic 
transmission. This diagram shows several of the mechanisms by which 
metabotropic receptors such as GPCRs can modify synaptic transmission. 
Gi-coupled GPCRs can attenuate pre-synaptic release by activating various 
channels, including inhibitory GIRKs (G protein–coupled inwardly rectifying 
potassium channels)18,128, and by inhibiting vesicle-release machinery, 
including SNARE proteins19. Post-synaptic Gq- and Gs-coupled GPCRs 
can induce or potentiate neuronal firing via varous intracellular second 
messengers129 and secondary modulation of ion-channel activity21. PKA, 
protein kinase A.
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Fig. 2 | the availability of chemical matter is useful for obtaining GPCR 
structures. a, Compounds annotated in Chembl (blue circles) plotted 
against a particular human GPCR (horizontal axis) versus the number 
of X-ray or cryo-EM structures deposited for each particular GPCR (red 
squares) (effective date, 1 February 2019). b, Comparison of the number 
of compounds annotated and the number of structures currently available 
shows that there is no direct linear relationship between these.
Finally, there is typically a large outward movement (of 10–15 Å) 
of the cytoplasmic end of TM6, which facilitates interactions with 
G proteins49 and other transducers53. In general, the ‘active-like’ 
receptor states in Fig. 3 show the various transitions mentioned 
above without the large outward movement of TM6.
Currently, there are two published structures of GPCRs in 
complex with β-arrestin-biased agonists, including LSD70 and 
ergotamine32 with the 5-HT2B serotonin receptor, and one struc-
ture of a G protein–biased ligand in complex with hetereotrimeric 
G protein for the GLP-1 receptor64. The β-arrestin-biased agonist 
structures (Fig. 3) seem to represent an ‘intermediate’ state between 
the signaling complex states and the inactive states. Notably, the 
sodium site is collapsed, with rearrangements of key residues that 
stabilize the bound sodium ion, including (with the Ballesteros–
Weinstein numbering convention71) Ser3.39 and Asp2.50 (Fig. 4a). 
Notably, Ser7.45 rotates in to occlude the sodium pocket (Fig. 4a). 
Additionally, a key residue (Leu209) in extracellular loop 2 (EL2) 
seems to form a ‘lid’ over LSD, retarding its dissociation and being 
essential for the recruitment of arrestin. A similar role for the same 
residue in EL2 was verified in studies of the D2 dopamine receptor 
and several other biogenic amine receptors61,62,72. Notably, the P-I-F 
and NPXXY motifs, along with conformational rearrangements in 
TM6 and TM7, are consistent with an intermediate activated state61 
(Fig. 4b). Collectively, these rearrangements suggest that concerted 
conformational changes involving residues throughout the recep-
tor, although they do not fully mimic the changes in the rhodop-
sin–arrestin complex63, are responsible for the arrestin-biased 
conformation that favors binding of arrestin (Fig. 4b). In contrast, 
the GLP-1 complex with the G protein–biased agonist exendin-P5 
shows the most pronounced difference in TM1, along with extra-
cellular regions of TM6, TM7 and extracellular loop 3 (EL3), for 
which there is support by extensive mutagenesis (details in ref. 64).
The inactive states typically show a conserved sodium site, with 
sodium visualized in the structures of highest resolution34,65,66. 
Additionally, a conserved ‘ionic lock’ between D/E3.49 (of the D(E)/
RY motif) and N6.30, which stabilizes the ground state of several 
GPCRs73,74, is occasionally seen. Remarkably, in an inactive state 
stabilized by Nb60 (nanobody 60) and carazolol67, this ionic lock is 
recapitulated by the nanobody. Additionally, in many inactive-state 
structures, the P-I-F, NPxxY and D(E)/RY motifs are all in a gener-
ally conserved ‘inactive-like’ state.
The studies discussed above demonstrate clear progress in 
the understanding of the structural features required for differ-
ent modalities of receptor activation and signaling. Clearly, much 
remains to be done in this direction, and the discovery of many 

























Fig. 3 | Structural validation of the extended ternary complex model 
of GPCR action. The extended ternary complex model6,68,69 predicts the 
existence of multiple interconvertible GPCR states stabilized by ligands 
(agonists, neutral antagonists and inverse agonists) and transducers  
(G proteins, arrestins and other transducers). The various high-resolution 
structures here have provided validation for this schema. These states 
include the following: inactive states stabilized by allosteric nanobodies 
(RL2)67; active sodium-bound (R*L)70 and inactive sodium-bound states66 
stabilized by agonists and inverse agonists, respectively; and coupled states 
(R*GL and R**LβArr). The model also provides for the possibility of biased 
signaling due to agonist-induced stabilization of distinct active and coupled 
states31,32 (e.g., R*L and R**L). Finally, spontaneously active states (R*) and 
coupled states (R*G), which have been demonstrated in many systems68, 
are predicted to exist, although structures of these are not yet available. 
βArr, β-arrestin. Each state for which a structure is known is presented with 
the Protein Data Bank accession code in parentheses directly above and a 
description of the structure at top. Here, * and ** represent distinct active 





















Fig. 4 | Structural rearrangements associated with distinct GPCR states. 
a, Rearrangements within the sodium pocket associated with stabilization 
of an arrestin-biased state of the 5-HT2B serotonin receptor: key residues 
involved in stabilizing sodium (Ser3.39 and Asp2.59), along with Ser7.45, 
collapse to occlude the sodium site. Green indicates the inactive sodium-
stabilized state of the D4 dopamine receptor; cyan shows the LSD-bound 
5-HT2B receptor (key). b, Rearrangements in the P-I-F motif associated 
with inactive (green), G-protein (magenta) and arrestin-biased (cyan) 
conformations (key).
Challenges and opportunities for drug design and discovery
Selectivity. Given the large number of GPCR structures and reason-
able coverage of some GPCR families, these structures should, at 
least in theory, be useful for the de novo design of selective drugs. 
This is particularly true when new ‘pockets’ are discovered, as was 
the case for the D275, D376 and D434 dopamine receptors. As shown 
in Fig. 5a–c, these structures revealed potentially unique binding 
surfaces that could be exploited for the design of selective ligands. 
Figure 5d shows a more detailed view of the D4 selectivity filter, 
while Fig. 5e shows how this is occluded in the D2 receptor34. Given 
that all three structures were obtained with chemically distinct 
and non-selective ligands, however, it is conceivable that the dif-
ferent binding pockets might simply reflect the fact that different 
ligands with distinct chemical scaffolds (e.g., different chemotypes) 
engage different residues in the receptors. One way to test the 
hypothesis that these different binding pockets are pharmacologi-
cally relevant is to create new ligands that are designed to engage 
these ‘selectivity filters’. For the D3 receptor, remarkable success was 
achieved77 with a compound with 1,700-fold selectivity for the D3 
receptor and minimal off-target activity (Fig. 5). Starting with the 
seed compound eticlopride (Fig. 5f), which is a potent and non-
selective D2 and D3 antagonist with weaker activity at D4, that 
group of researchers77 used a combination of docking and medici-
nal chemistry to identify a potential modified scaffold predicted to 
target a putative selectivity region within the D3 receptor previously 
identified by mutagenesis and molecular modeling76 (Fig. 5g). Via 
this structure-inspired design approach, compound 19 (Fig. 5g) was 
eventually synthesized and was found to be a potent and selective 
D3 antagonist.
An alternative approach is to target such ‘selectivity filters’ via 
automated docking (Fig. 5c–e,h). In an initial proof-of-concept 
study, the D4 dopamine receptor selectivity filter was targeted by 
a docking screen of 600,000 commercially available compounds34 
from the ZINC database78. A set of ‘seed’ compounds discovered 
from the initial docking screen was further optimized by dock-
ing and subsequent identification of analogs; that ultimately led to 
the highly selective D4 partial agonist compound 9-6-2434, which 
was >1,000-fold selective for the D4 receptor and lacked activity at 
320 other GPCRs.
Subsequent to that, the computational approach has been 
enhanced by automated docking-based screening of ultra-large 
libraries in a screen with 138 million drug-like compounds. 
This in silico screening, wherein each compound was docked in 
>100,000 conformations, required the analysis and scoring of 70
trillion docking events79 (Fig. 5h). In this study79, the previously
identified D4 selectivity filter34 composed of the pocket formed by
residues Leu3.28 and Phe2.61 (Fig. 5c–e) was again computationally
targeted. That docking screen led to the discovery of a large num-
ber of chemically novel and highly selective D4 ligands. Of these,
ZINC621433144 (Fig. 5h) was the most potent of the agonists
tested, with a median effective concentration (EC50) of 180 pM and
selectivity for D4 over D2 and D3 (Fig. 5h). On the basis of the rate 
of true positive results among the predicted active compounds, the 
authors estimate that as many as 400,000 distinct D4-active com-
pounds with more than 70,000 diverse chemotypes79 could exist
in the library of 138 million compounds. Similar, albeit less com-
putationally intensive, docking-based approaches have yielded
selective ligands for the 5-HT1B serotonin receptor80, κ-opioid
receptor81, D2 dopamine receptor81 and other receptors (reviews
available in refs. 8,82).
Structure-guided design of biased ligands
Functional selectivity, also known as ‘biased signaling’83, has been 
defined as the process by which “...ligands induce (or stabilize) 
unique, ligand-specific receptor conformations…result(ing) in dif-
ferential activation of signal transduction pathways associated with 
that particular receptor”83. The phenomenon of functional selec-






























Fig. 5 | Structure-guided design of selective GPCR ligands for dopaminergic modulating neurotransmission. a–c, Solved structures of the three members 
of the D2 family of dopamine receptors: D2 (ref. 75), in magenta (a); D3 (ref. 76), in cyan (b); and D4 (ref. 34), in green (c). d, Location of the D4 selectivity 
filter, with nemonapride bound in green. e, The selectivity filter in d is occluded in the D2 receptor (D2 residues in magenta). f–h, As described in the 
text, the D3 receptor structure was used to modify the non-selective D3 inverse agonist eticlopride (f) to compound 19 (g), which has high affinity and 
selectivity. Alternatively, ultra-large scale docking led directly to ZINC621433144 (h) which emerged as a picomolar potent and selective D4 agonist79. 
Affinities for eticlopride are from ref. 130.
preferential activation of different G proteins (e.g., G protein–sub-
type bias), a preference for G-protein signaling over arrestin (e.g., 
G-protein bias) or a preference for arrestin signaling over G pro-
teins (e.g., arrestin bias). Reports of functional selectivity at GPCRs
have appeared for many decades (an example of this is in ref. 84),
and such bias is now recognized as a nearly universal phenomenon
for GPCRs6. Indeed, there are now multiple reports of the discov-
ery and optimization of arrestin-biased ligands85,86 and G protein–
biased ligands87–89 for many GPCRs (reviews available in refs. 6,90,91).
As mentioned above, so far there is only one structure of a GPCR
(a GLP-1 receptor) in complex with a G protein–biased ligand
(peptide exendin-P5) and hetereotrimeric G proteins64, a handful
of structures of arrestin-biased ligands in complex with the 5-HT2B
serotonin receptor32,62,70, and no structures of arrestin-biased ligands 
in a GPCR–arrestin complex. Thus, although there is a paucity of
structural information on GPCR functional selectivity, there have
been several reports in which structure-informed and structure-
inspired design of neurotransmitter-targeted G protein and arres-
tin-biased ligands have been achieved.
For example, the discovery of G protein–biased agonists for the 
μ-opioid receptor has been reported92, although this discovery was 
accomplished without knowledge of any of the structural features 
responsible for biased signaling. In that study, molecular docking of 
3 million compounds was performed against the inactive conforma-
tion of the μ-opioid receptor targeting a highly conserved aspartic 
acid (Asp3.32) and engaging a conserved water network and a tyrosine 
residue (Tyr3.33) putatively involved in selectivity and agonist activity. 
Compounds with predicted activity were tested for functional activ-
ity at G protein and arrestin signaling and, after several rounds of 
medicinal chemistry optimization, PZM21 was identified as a 
potent and efficacious G protein–biased agonist92. Similar G pro-
tein–biased ligands have been discovered for μ-opioid receptors93,94 
and κ-opioid receptors89,95, although these were not informed by 
structural determinants. On the other hand, via a combination of 
molecular dynamics and synthetic studies, a derivative of salvinorin 
A96 was discovered for μ-opioid receptors97 that is G protein biased 
and thus probably has less potential for abuse. Similarly, in a study 
of κ-opioid receptors, residues identified from structural studies as 
being essential for biased signaling ultimately led to the creation of 
novel structure-guided G protein–biased opioid agonists52.
A structure-inspired approach72 for the creation of biased ligands 
at aminergic GPCRs, all of which are essential targets for the neu-
rotransmitters serotonin, norepinephrine, dopamine and histamine, 
proved successful as well. For this study72, the authors took advan-
tage of prior studies indicating that interactions with TM5 serine 
and other residues are essential for G-protein signaling62 at amin-
ergic GPCRs, while interactions with EL2 residues can be essential 
for arrestin signaling61. Via a combination of molecular modeling, 
molecular dynamics simulations, automated docking and synthesis, 
the arrestin-biased compound 7 was discovered for the D2 dopa-
mine receptor72 (Fig. 6a). As previous studies have shown that such 
arrestin-biased compounds may have efficacy in the treatment 
of schizophrenia and related neuropsychiatric disorders85,98, this 
could represent a useful approach for optimizing arrestin-biased 
medications for the treatment of neuropsychiatric disorders. 
Finally, it is also worth mentioning that biased signaling might be 
influenced at the level of recruitment of and receptor phosphoryla-
tion by GPCR kinases99, and that this potentially can be influenced 
by GPCR ligands.
Orphan and understudied GPCRs. As previously mentioned, 
nearly 50% of GPCRs, most of which are highly expressed in the 
brain14, have a paucity of known ligands. Even for those neurotrans-
mitter receptors that have been the subject of intensive investiga-
tion, such as muscarinic and dopamine receptors, the identification 
of suitably selective ligands for the various subtypes continues to be 
challenging. Thus, for example, there are no truly selective agonists 
for D5 dopamine or M5 muscarinic receptors, although a modestly 
selective D5 antagonist100 and a fairly selective M5 antagonist101 
have been reported. Unfortunately, off-target pharmacology has not 
been reported for these compounds, so their selectivity over other 
GPCRs is unknown.
Although there are no published structures of orphan or under-
studied brain GPCRs (oGPCRs38), the use of homology models 
and automated docking has provided a structure-inspired approach 
for ligand discovery. Thus, for example, an integrated approach 
using parallel screening, homology modeling, docking and 
analog synthesis led to ogerin — a selective positive allosteric modu-
lator for GPR68 — and selective negative allosteric modulators 
for GPR65102 (Fig. 6b). The allosteric modulator ogerin was 
demonstrated to affect learning and behavior in mice, which 
indicates that GPR68 is a potentially important GPCR in the 
brain102. A similar approach led to the discovery of selective ago-
nists for the oGPCR MRGPRX2, which is involved in pain and 
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Fig. 6 | Structure-inspired design of ligands for GPCRs to modulate 
synaptic transmission. a, Strategy for the design of ligands with arrestin 
bias for biogenic amine neurotransmitter receptors72 (details in text). Here, 
through the use of a combination of molecular dynamics simulations, 
docking and medicinal chemistry, compounds were created that were 
predicted to interact with a conserved EL2 residue that can impart arrestin 
bias. b, Computational strategy for the discovery of small-molecule 
probes with which to modulate oGPCRs such as GPR68102 Here, 3.1 million 
compounds were docked to a model of GPR68 and then, via iterative 
docking and testing of analogs, ogerin was identified as a selective GPR68 
positive allosteric modulator.
https://doi.org/10.1038/s41594-019-0252-8
substance P and other peptides103. These approaches are facilitated 
by parallel screening approaches in which hundreds of oGPCRs 
can be screened simultaneously102,104; active compounds are used to 
inform homology models for docking and subsequent discovery of 
new ligands102,103,105–107.
Genetic and model organism studies are also facilitating 
understanding of the potential therapeutic importance of oGP-
CRs for neuropsychiatric disease. Thus, a published study has 
indicates that the oGPCR MRGPRX4 is involved in the pain 
and itch sensations mediated by bile acids108 Another study has 
shown that MRGPRX4 is also essential for the preference for 
menthol cigarettes in certain ethnic populations109. Given the 
distribution of MRGPRX4 in peripheral nerves, it is likely that 
MRGPRX4 and related receptors are neurotransmitter recep-
tors involved in peripheral sensations such as pain and itch110. 
Databases devoted to the brain distribution of oGPCRs39,111,112 
should facilitate discovery of their endogenous neurotransmit-
ters, their function and neuropsychiatric implications for patho-
genesis and treatment.
Polypharmacology. Historically, the most effective drugs for many 
complex neuropsychiatric diseases have targeted multiple GPCRs 
and other molecular targets9,113. It is now understood that this is 
probably because of the exceedingly complex genetic landscape of 
common diseases in which hundreds to thousands of genes might 
exert small effects114. This has led to the understanding that com-
plex diseases are omnigenic rather than polygenic114, meaning 
that nearly every gene may ultimately exert a small effect on core 
disease pathways. Perhaps not surprisingly, the desire to discover 
increasingly selective drugs has resulted in lower overall success 
rates of drug-discovery screens115. Such a lack of success has led 
to the hypothesis that generating polypharmacological drugs 
with designated multiple targets represents a useful approach 
for the treatment of complex diseases113,116. For aminergic 
GPCRs, there has been some success in discovering the 
structural features responsible for polypharmacological activi-
ties33, which comprise a series of nine semi-conserved residues 
(Asp3.32, Ile/Val3.33, Cys3.36, Thr3.37, Ala/Ser/Thr5.46, Trp6.48, Phe6.51, 
Phe6.52 and EL2 Val/Ile/Leu). Although in theory, structure-
guided approaches should be helpful for the discovery and 
design of polypharmacological drugs, so far, this has not been 
entirely successful117,118
therapeutic and commercial opportunities for  
structure-guided GPCR drug discovery
Heptares (acquired by Sosei in 2016)119, and Receptos (acquired by 
Celgene in 2015)120, along with Conformetrix121, have invested con-
siderable resources in bringing GPCR structure-guided drug dis-
covery to fruition. So far, publicly available information indicates 
that the exemplar compounds are targeted mainly to well-studied 
GPCRs for which selective ligands are difficult to obtain. Thus, for 
example, Heptares has advanced an M4-selective agonist to phase I 
trials, presumably for cognition enhancement (https://clinicaltrials.
gov/ct2/show/NCT03244228?term=heptares&rank=4). Heptares 
has also brought a structure-guided mGlu5 negative allosteric 
modulator122 for metabotropic glutamate receptors to initial phase 
I trials, presumably for application to the central nervous system 
(https://clinicaltrials.gov/ct2/show/NCT03785054?term=heptare
s&rank=2). Receptos, in partnership with Celgene, has advanced 
RPC1063, an S1P receptor agonist for the treatment of multiple 
sclerosis (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
detailedIndex.cfm?cfgridkey=611517), to phase III clinical trials.
Future directions
Given the wealth of structural information now available for many 
GPCRs, it is anticipated that structure-guided approaches will 
eventually lead to neuropsychiatric medications with greater effi-
cacy and fewer side effects. As on-target and off-target side effects, 
along with clinical effectiveness and safety, continue to be major 
drivers of drug failures in clinical trials123, insights into the struc-
tural basis of ligand engagement could provide new opportunities 
for GPCR-based neuropsychiatric drug discovery. Thus, where a 
G protein–biased ligand might show greater efficacy and fewer side 
effects, insights into the structural basis of such bias could acceler-
ate the discovery of novel chemotypes with biased signaling pat-
terns. Indeed, this approach has been successful in the generation 
of biased tool compounds for many neurotransmitter receptors, 
including D4 dopamine receptors34,124, μ-opioid receptors92 and 
other receptors62,72. Although there are currently no structure-
guided biased drugs in clinical trials, encouraging results have 
appeared for TRV130 as a G protein–biased opioid receptor ago-
nist for pain125, albeit with some abuse liabilities, as manifested in 
preclinical studies126,127.
As is clear from the foregoing, the past decade has witnessed 
astounding progress in understanding of the structure and func-
tion of metabotropic receptors for neurotransmitters. This 
increasing wealth of structural information, as well as advances 
in structure-guided and structure-inspired drug discovery, prom-
ise to accelerate the discovery of drugs that target metabotropic 
receptors for neurotransmitters with improved efficacies and 
fewer side effects.
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